CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

CNS Specific Antisense Oligonucleotide Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Antisense oligonucleotides are synthetic strings of nucleic acid, which reduce expression of messenger RNA (m-RNA). The function performed by interference with pre m- RNA splicing are restoration of protein and modification of protein. Antisense oligonucleotide is a new approach to treat several neurodegenerative disorders to prevent disease onset or stop disease development.
Market Dynamics
Increasing prevalence of neurodegenerative disease is a major factor driving CNS specific antisense oligonucleotide market growth. According to fact sheet from Alzheimer Association, an estimated around 5.7 million Americans were diagnosed with Alzheimer's dementia in 2018. Moreover, rich product pipeline for the treatment of CNS disorders and rare diseases associated with it is expected to boost the market growth. For instance, in December 2018, Biogen and Ionis Pharmaceuticals product IONIS-SOD1Rx (BIIB067) cleared Phase 1 clinical trial and is expected to be launched by 2020.
Key features of the study:
This report provides in-depth analysis of the CNS specific antisense oligonucleotide market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global CNS specific antisense oligonucleotide market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., Q-STATE BIOSCIENCES, INC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global CNS specific antisense oligonucleotide market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the CNS specific antisense oligonucleotide market

Detailed Segmentation:
Global CNS Specific Antisense Oligonucleotide Market, By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx (RG6042)
Global CNS Specific Antisense Oligonucleotide Market, By Indication:
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular Atrophy
Huntington’s Disease
Global CNS Specific Antisense Oligonucleotide Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global CNS Specific Antisense Oligonucleotide Market, By Geography:
North America
By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx (RG6042)
By Indication:
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular Atrophy
Huntington’s Disease
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country:
U.S.
Canada
Latin America
By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx (RG6042)
By Indication:
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular Atrophy
Huntington’s Disease
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx (RG6042)
By Indication:
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular Atrophy
Huntington’s Disease
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx (RG6042)
By Indication:
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular Atrophy
Huntington’s Disease
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx (RG6042)
By Indication:
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular Atrophy
Huntington’s Disease
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug:
Approved
Patisiran
Nusinersen
Inotersen
Pipeline
IONIS-HTT Rx (RG6042)
By Indication:
Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy
Spinal Muscular Atrophy
Huntington’s Disease
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Country:
South Africa
Central Africa
North Africa
Company Profiles
Alnylam Pharmaceuticals Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Sarepta Therapeutics Inc.
Biogen Inc.
Ionis Pharmaceuticals Inc.
Wave Life Sciences Ltd.
Stroke Therapeutic Inc.
Dynacure
ProQR Therapeutics N.V.
Q-STATE BIOSCIENCES, INC.
“*” marked represents similar segmentation in other categories in the respective section.